The research, carried out at Imperial College London and the University of Warwick, suggests these signals could be targets for drugs that would help prevent miscarriage in women who are particularly vulnerable.
At the start of pregnancy, the fertilised embryo must embed itself in the lining of the uterus. The uterus is only receptive to embryos for a few days in each menstrual cycle, ensuring that embryos can only implant at the right stage of development. Currently scientists know only a few details about the biological processes that control when an embryo can be implanted.
In the latest study, published in the journal PLOS ONE, researchers studied chemical signals produced by human cells, taken from the lining of the uterus and grown in the lab. They identified a key role for a molecule called IL-33, which the cells secrete during the receptive phase and which influences the activity of nearby cells.
Normally, the effects of IL-33 and other chemical signals in the lining of the womb are short-lived, which helps to ensure that woman can only conceive during a narrow window. In cells from women who had suffered three or more miscarriages however, high levels of IL-33 continued to be secreted for 10 days, suggesting that the receptivity of the uterus was not being controlled properly in these women.
The study also looked at the effects of these molecular signals on fertility in mice. The researchers treated the uteruses of the mice with chemicals secreted by cells from the human womb lining. They found that chemicals produced by cells from women with repeated miscarriages extended the time during which mice could become pregnant, but also made miscarriages more likely. The researchers conclude that a prolonged window of fertility increases the risk of abnormal embryos implanting. In addition, it is associated with inflammation in the lining of the womb, which compromises the development of healthy embryos.
Dr Madhuri Salker, a study author from the Department of Surgery and Cancer at Imperial College London, said: "Our study suggests that in women who have had successive miscarriages, the mechanisms that control whether the womb can accept and support an embryo don't work properly. This might mean they can become pregnant with poor quality embryos or that the embryo implants in an unsupportive environment, which would seriously compromise the chances of a successful pregnancy."
The senior author of the study, Professor Jan Brosens from the University of Warwick, said: "The molecular signals we identified are known to be involved in a range of diseases, including Alzheimer's, asthma and heart disease. Our findings suggest that targeting these molecules might also be a promising strategy for developing treatments that would prevent miscarriages in women who are especially vulnerable."
The research was supported the Biomedical Research Unit in Reproductive Health, a joint initiative between the University Hospitals Coventry and Warwickshire NHS Trust and Warwick Medical School, and the Genesis Research Trust.
For further information please contact:
Research Media Officer
Imperial College London
Out of hours duty press officer: 44-780-388-6248
Notes to editors
1. M.S. Salker et al. (2012) 'Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss.' PLOS ONE 7(12): e52252. doi:10.1371/journal.pone.0052252
The paper is free to view and download at http://dx.
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Health Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.